INTRODUCTION
Cancer genomes contain not only cancer-causing ''driver'' mutations, but also many additional accumulated ''passenger'' mutations that do not contribute directly to the tumor phenotype (Stratton et al., 2009) . A key challenge in cancer research is to distinguish the consequential driver mutations from the inconsequential passenger mutations. Given the recent explosion in the number of sequenced cancer genomes, this challenge is particularly pressing (Vogelstein et al., 2013) .
Decades of research have revealed that somatic mutations affect cancer genes through diverse molecular mechanisms. For example, oncogenes can be activated by amino acidaltering missense mutations, by amplifications, and by translocations. Tumor suppressor genes, in contrast, are inactivated by local or large-scale deletions and loss of heterozygosity, by the introduction of premature stop codons or frameshifts, and by mutations in introns that inactivate pre-mRNA splice sites (Vogelstein et al., 2013) . In the large-scale analyses of cancer genomes performed to date, it is these previously established common mechanisms that have been considered (Stratton et al., 2009; Vogelstein et al., 2013) .
However, the extent of sequence data that are now available for tumor samples should also allow the identification of additional classes of common oncogenic mutations. If such new types of driver mutations exist and they are not considered, then our ability both to interpret cancer genomes in general and to understand the causes of oncogenesis in individual patients would be compromised.
The universal genetic code uses 61 codons to encode 20 amino acids. The redundancy in this code means that many nucleotide changes can be made in the sequence of a gene without affecting the sequence of the encoded protein. Synonymous or ''silent'' positions in a gene's sequence can be used to encode additional information that affects properties such as the speed or accuracy with which an mRNA is translated (Drummond and Wilke, 2008) , how an mRNA is folded (Goodman et al., 2013) or spliced (Parmley et al., 2006) , or, through translational pausing, how a protein folds (Zhang et al., 2009; Zhou et al., 2013) . These and other mechanisms mean that changes in a gene's sequence that are silent with respect to protein sequence are not always silent with respect to function (Gingold and Pilpel, 2011) . Indeed, there is growing evidence that natural selection acts widely on synonymous sites (Drummond and Wilke, 2008; Supek et al., 2010) .
Based on their evolutionary importance, individual examples (Gartner et al., 2013; Griseri et al., 2011; Ma et al., 2009; Schutz et al., 2013) , and their potential role in other human diseases (Sauna and Kimchi-Sarfaty, 2011) , we hypothesized that synonymous mutations might also frequently contribute to cancer. Here, in an analysis of >3,000 cancer exomes and >300 cancer genomes, we present robust statistical evidence that this is indeed the case: that synonymous mutations must frequently contribute to cancer. These silent mutations in exons may act through diverse molecular mechanisms, and they are often associated with changes in splicing.
RESULTS

Employing Matched Gene Sets to Control for Regional Variation in Mutation Frequencies in Cancer Exome Data
Previous studies have distinguished cancer-causing driver mutations from background passenger mutations by comparing the frequency of protein-coding changes to the frequency of synonymous mutations in the same genes (Ding et al., 2008; Peifer et al., 2012) . However, a search for selection acting on synonymous mutations necessarily has to rely on a different approach.
We used the Cancer Gene Census (CGC) (Futreal et al., 2004; Santarius et al., 2010) to define three sets of known oncogenes according to their mechanism of activation and a set of known tumor suppressor genes ( Figure 1A ). Additionally, we collected a larger set of cancer genes consisting of those reported as recurrently mutated in 34 recent cancer genome sequencing studies (Table S1 available online). For each of these gene lists, we ran an optimization procedure to create a set of non-cancer genes matching the cancer gene list in the distribution of their regional point mutation rates at 200 kb and 1 Mb resolution and also for a set of features implicated in mutation rate variation (the heterochromatin-associated nucleosome modification H3K9me3, replication timing, base composition [GC 3 content] and mRNA expression levels) across tissues (Hodgkinson et al., 2012; Pleasance et al., 2010; Schuster-Bö ckler and Lehner, 2012; Woo and Li, 2012) ; the complete list of features is given in Table S2 , and a principal components plot summarizing Figure S7 and Tables S1 and S2. the relationships between these features is shown in Figure 1B . For instance, the 39 recurrently mutated oncogenes from the CGC are situated in genomic regions with significantly higher mutation rates, higher levels of heterochromatin, and later replication times ( Figure 1C ), and they are also more highly expressed than the general gene set ( Figure 1C ). The matched set here consists of 1,517 genes that closely follow the 39 oncogenes in all of these features. In contrast, the 38 recurrently mutated tumor suppressor genes lie in significantly less mutable, less heterochromatic, and earlier replicating regions of the genome ( Figure 1D) ; the corresponding matched set again compensates for these differences ( Figure 1D ).
Oncogenes, but Not Tumor Suppressor Genes, Contain an Excess of Somatic Synonymous Mutations in Human Tumors
We next compiled a data set of 292,405 missense and 123,193 synonymous somatic mutations identified in the exomes of 3,851 cancer samples. These include tumors from 11 different tissues with more than 200 samples each (Table S2) . As expected, missense mutations are enriched in previously reported oncogenes and tumor suppressor genes ( Figure 2A) . Strikingly, however, oncogenes known to be activated by missense mutations are also enriched for synonymous mutations in the 3,851 cancer exomes (Figure 2A) , with a 23%-30% excess of synonymous mutations compared to genes in their matched control set (p = 3 3 10 À6 and p = 7 3 10 À10 ; Figure 2A ). In contrast, this is not the case for tumor suppressor genes, which actually show a slight depletion for synonymous mutations ( Figure 2A ). To further test for any additional unaccounted source of variation in mutation rates, we also quantified the enrichment of mutations in introns. In all cases, the enrichments of mutations in the introns of oncogenes and tumor suppressors compared to the matched gene sets were close to 1 ( Figure 2D ). Importantly, the intronic mutation rates of the oncogenes were not elevated compared to the matched sets when assessed both in the set of 176 whole-genome sequences used in the matching procedure (1.033 and 1.043; Figure 2D ) and in an independent set of 219 genomes (1.053 and 1.043; Figure 2D ). Moreover, the oncogenes' UTRs were not enriched with mutations compared to the matched sets (0.963 and 0.973; Figure 2D ). This is in contrast to the synonymous mutation frequency, which is similarly elevated in the set of whole-genome sequences (1.273 and 1.323; Figure 2D ). Thus, increases in local mutation rates cannot account for the elevated synonymous mutation rates in oncogenes. The mutation spectra of synonymous mutations in oncogenes closely reflect those of their matched sets ( Table S3 ), meaning that differences in sequence composition do not underlie the observed increases in synonymous mutation rates. Moreover, oncogenes are highly enriched for synonymous mutations compared to other gene functional categories (p = 0.014; histogram in Figure 2B ). Finally, bootstrapping to remove bias (Figure S1 ) resulted in a slightly higher estimate of synonymous enrichment of the oncogenes (1.343; Figure 2C ) as well as an estimate of a confidence interval (CI) that accounts for the variance of the matching algorithm (95% CI: 1.18-1.49).
Considering Mutations in Introns and in Neighboring Genes Confirms the Excess of Synonymous Mutations in Oncogenes
We validated our findings using two additional methodologies that are orthogonal to the matched-sets approach. First, we compared the synonymous mutation rates in oncogenes to those in neighboring genes in the genome. Whereas tumor suppressor genes and amplification-or translocation-activated oncogenes show no evidence of an elevated frequency of synonymous mutation compared to their neighbors ( Figure 2E ), missense-activated oncogenes have an excess of synonymous mutations (1.203 and 1.373 for the two gene sets; Figure 2E ), strikingly similar to that determined using the mutation-rate matched gene sets.
Second, we employed the Invex randomization test (Hodis et al., 2012) that simulates mutations in the coding sequence by sampling from the intronic and UTR mutations of the same gene. This test stringently controls for variations in mutation rates and spectra. The Invex test estimates 1.203 and 1.253 increased synonymous mutation rates in oncogenes ( Figure 2F ). We also compared the rates of missense mutations determined using this method to those determined using the Invex test and again found a striking agreement (R 2 = 0.991 across cancer gene classes; Figure S1 ), further validating the matched-sets approach.
Co-Occurring Mutations Do Not Account for the Excess of Synonymous Mutations in Oncogenes
One possible explanation for the enrichment of synonymous mutations in oncogenes is that they represent the phenomenon of clustered mutations or ''mutation showers'' (Roberts et al., 2012; Wang et al., 2007) . For example, if a mutation process generates multiple mutations in a gene, then functionally neutral synonymous mutations could be enriched in oncogenes because of ''hitchhiking'' with missense mutations that are positively selected. However, this model cannot explain the enrichment of synonymous mutations in oncogenes, because samples harboring missense mutations in a particular oncogene are unlikely to also harbor synonymous mutations in the same gene (odds ratio [OR] = 0.53, p = 3 3 10 À6 ; Figure 2J ). This avoidance is even stronger in the oncogenes most frequently mutated in a particular tissue (OR = 0.29, p = 4 3 10 À8 ; Figure 2J ). Moreover, such strong avoidance is not observed for tumor suppressor genes, where we see no enrichment for synonymous mutations ( Figure 2J ). Consistently, if we filter out all synonymous mutations in genes already harboring a nonsynonymous mutation in the same sample, the synonymous enrichment of oncogenes is retained (1.223, p = 4 3 10 À5 ; Figure 2K ), as is also the case when removing all synonymous mutations occurring on chromosomes containing any additional nonsynonymous mutations in any gene ( Figure 2K ; p = 0.003).
Synonymous Mutations Are Selected for in a TissueSpecific Manner
The frequency of missense mutation in individual oncogenes is not evenly distributed across tissues. For example, the oncogene BRAF is frequently mutated in melanoma, whereas KRAS is frequently mutated in colorectal cancer. We quantified the frequencies of synonymous mutations separately for cancers of different tissues and observed a consistent trend of enrichment in the oncogenes and depletion in the tumor suppressors across the 11 tissues ( Figure 2G ). The enrichment of synonymous mutations in oncogenes is lower in tissues with a high mutational load (1.10-1.263 in lung, melanoma, or head and neck cancers; Figure 2H) and stronger in tissues with a low mutational load (1.44-1.593 in leukemia, breast, and ovarian cancer; Figure 2H ), consistent with a lower signal-to-noise ratio in highly mutated genomes. When considering individual tissues, synonymous mutations are enriched in the same tissue-specific oncogenes (list in Table S4 ) as missense mutations ( Figure 2H ; median synonymous enrichment over tissues = 1.983 compared to median = 1.293 for the complete oncogene set; p = 1.3 3 10
À3
). This is not the case for tumor suppressor genes ( Figure 2I ; median enrichment = 0.723). Again, this is not due to synonymous and missense mutations co-occurring in the same genes in the same sample ( Figure S2 ; median enrichment = 1.843; p = 5 3 10 À3 ). Tissue-specific oncogenes do not exhibit different dinucleotide compositions in their exons ( Figure S2 ), making it unlikely that tissue-specific mutational processes underlie this enrichment. Thus, in a particular tissue, synonymous and missense mutations tend to target the same oncogenes.
Cancer-Associated Synonymous Mutations Preferentially Target Conserved Sites and Particular Regions of Oncogenes
The molecular mechanisms by which synonymous mutations can affect gene activity are diverse (Sauna and Kimchi-Sarfaty, 2011) . However, we reasoned that some molecular mechanisms might be more common than others, and so we identified a group of 16 known oncogenes with a high (>1.53) enrichment with synonymous mutations for further analysis of putative molecular effects ( Figures 3A-3C ). Within this set, 11 genes are also individually significantly enriched with synonymous mutations (false discovery rate [FDR] < 9%). These are the receptor tyrosine kinases PDGFRA, EGFR, KDR (VEGFR2), and NTRK1, the receptors IL7R and TSHR, the structural protein ELN, the cytoplasmic kinases JAK3 and ITK, and the transcription factors GATA1 and RUNX1T1. In addition to this set, the oncogenes ALK and NOTCH2 are also individually significant, at 1.473 and 1.463 enrichment. The increased synonymous mutation rates in these genes are not associated with a comparable increase in intronic and UTR mutation rates ( Figure 3D ; p = 5.7 3 10 À4 ), ruling out a role for an elevated local mutation rate. In addition to the above oncogenes, a tissue-specific synonymous enrichment could be detected for other genes, most consistently for the JAK2 and RET kinases and for the SF3B1 splicing factor (at least two tissues at FDR % 10%; list in Table S5 ). First, we considered whether cancer-associated synonymous mutations preferentially target evolutionarily conserved synonymous sites (Lin et al., 2011) and found that this was indeed the case ( Figure S1 ). This enrichment is not observed for tumor suppressors ( Figure S1 ) and is confirmed using an alternative measure of sequence constraint (Pollard et al., 2010) ( Figure S1 ). Missense mutations are known to cluster together in the linear sequence of oncogenes, reflecting the arrangement of functionally important sites in a protein.
Synonymous mutations also significantly cluster in known oncogenes ( Figure 3E ) and even more so in the top-16 oncogene set, where a synonymous mutation is more likely to occur within five codons of another synonymous-mutated site (OR = 1.74, p = 10 À6 ; Figure 3E ), an effect size similar to the missense-missense clustering in the same genes (OR = 1.92; Figure 3F ). Again, such an association is absent in tumor suppressors for synonymous mutations (OR = 0.94), but not, as expected, for missense mutations (OR = 2.29). Interestingly, we found that the synonymous mutations in the 16-oncogene set also cluster significantly with the missense mutations, albeit to a lesser extent (OR = 1.24; Figure 3G) . The clustering of the synonymous mutations is not due to hitchhiking effects, because it is not altered after removing cases where the gene also contained a nonsynonymous mutation in the same sample (OR = 1.71, p = 2 3 10 À5 ;
striped bars in Figure 3E ). Individual examples of clustered mutations are shown in Figure 4I and 4H, with the complete set in all highly enriched oncogenes in Figure S3 .
Cancer-Associated Synonymous Mutations Do Not Frequently Increase Codon Optimality or mRNA Stability or Inactivate Exonic miRNA Target Sites Next, we considered the possibility that cancer-associated synonymous mutations function by increasing the use of more optimal codons, thereby enhancing the efficiency or accuracy of oncogene translation (Drummond and Wilke, 2008) . However, we found no evidence that cancer-associated synonymous mutations, considered as a set, increase codon optimality (Figure S4) , as judged using the genomic tRNA gene copy number (Table S6) . We also considered the potential influence of synonymous mutations on mRNA secondary structure, which is also known to affect translation efficiency (Goodman et al., 2013) . However, the computationally predicted mRNA structures (Markham and Zuker, 2008) in 50 and 100 nt windows overlapping synonymously mutated sites did not show a general tendency toward more open structures when mutated ( Figure S4 ). We also considered that synonymous mutations might affect oncogene expression by abolishing exonic microRNA (miRNA) target sites (Brest et al., 2011) but again found no evidence for this, considering either all sites or only those with evidence of evolutionary conservation at synonymous sites ( Figure S4 ). Therefore, effects on codon optimality, mRNA folding, and miRNA targeting do not seem to be common mechanisms by which synonymous mutations influence oncogene activity, although they may still be important in individual cases (Gartner et al., 2013) .
Synonymous Mutations in Oncogenes Target Exonic Splicing Motifs
An additional step in gene expression influenced by synonymous mutations is pre-mRNA splicing, with coding exons containing both exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) motifs that are under evolutionary constraint (Keren et al., 2010; Parmley et al., 2006) and with variants in these exonic motifs leading to altered splicing (Cartegni et al., 2002) . Mutations in intronic splicing donor or acceptor sites are a common mechanism of tumor suppressor gene inactivation, and changes in splicing can also deregulate the activity of oncogenes (Druillennec et al., 2012; Kaida et al., 2012) . Changes in splicing were also recently identified as a mechanism of acquired drug resistance in the BRAF (Poulikakos et al., 2011) and AR genes, where the underlying causes were either unknown (for BRAF) or intragenic deletions (AR). Consistent with a role in splicing, synonymous mutations in the 16-oncogene set are 1.753 enriched within 30 nt of an exon boundary in oncogenes ( Figure 4A ; p < 10 À4 ), but not in tumor suppressor genes ( Figure 4A ). Moreover, using the results of a study that tested all possible hexamers for ESE or ESS activity (Ke et al., 2011) revealed that cancer-associated synonymous mutations close to exon boundaries preferentially result in the gain of ESE motifs and the loss of ESS motifs ( Figure 4B ). This is not the case for synonymous mutations in tumor suppressor genes ( Figure 4B ). The same trends are seen when considering motifs identified by screening a random oligonucleotide library for ESS activity using an in vivo splicing reporter system (Wang et al., 2004 ) ( Figure 4C ). The ESE motifs identified through a statistical analysis of exon composition (Fairbrother et al., 2002) also predict that cancer-associated synonymous mutations tend to create ESEs in oncogenes ( Figure 4D ), but not in tumor suppressors. Across the three definitions of ESE/ESS, 
(B-D) Enrichments of synonymous mutations within 30 nt of SS that lead to exonic splicing silencer (ESS) or exonic splicing enhancer (ESE) gain or loss events. y axes display odds ratios versus different baselines, counting those mutations leading to a gain/loss of an ESE/S; p values by c 2 test. Error bars are 95% CI of the odds ratio. (E) Cumulative histograms of SS agreement to consensus motif for exons with above-versus below-median densities of synonymous mutations. D+ is the Kolmogorov-Smirnov (K-S) statistic. p value is from the two K-S tests combined using Fisher's method. PWM, position weight matrix. (F and G) Sequence contexts around synonymous mutations leading to ESE gains (F) or to ESS losses (G) clustered. Similar known motifs of ESE/ESS binding proteins shown for comparison. Bar charts show number of sequences above binding threshold for splicing factors (F) or in searches for similar motifs among RNA binding proteins (G). (A)-(G)
show data for the 16 oncogenes most enriched with synonymous mutations.
comparing the synonymous against the missense mutations in the same genes as a baseline gives a similar result: the synonymous mutations tend to lead to ESE gains and ESS losses more often than the missense mutations ( Figures 4B-4D ). Moreover, randomizing the positions of the synonymous mutations strongly reduces or abolishes the enrichments ( Figures 4B-4D ), meaning that the enrichment cannot be explained by an increased density of ESE/ESS elements in the oncogenes. ESE and ESSs tend to play more important roles in exon definition when the flanking splice sites are weaker, i.e., more divergent from the consensus splice site sequences (Fairbrother et al., 2002) . Consistent with this, we found that exons of the 16-oncogene set that harbor more synonymous mutations tend to have weaker splice sites ( Figure 4E ; p = 0.019). Clustering the sequences in the close vicinity of the ESE/ESSaltering synonymous mutations (±5 nt, because ESE/ESS are hexamers), we found one dominant cluster that encompasses 43% of examined ESE gain events ( Figure 4F ) and two large clusters for the ESS losses, encompassing 22% and 20% of ESS losses ( Figure 4G ). The consensus sequence of the ESE cluster is compatible with the known binding site of the SRSF1 (SF2/ ASF) splicing factor ( Figure 4F ), which can act as a potent oncoprotein (Karni et al., 2007) . Moreover, a cluster of ESS loss sequences closely matches the known binding site of the heterogeneous nuclear ribonucleoprotein (hnRNP) H2 splicing factor ( Figure 4G ). Previously, hnRNP H2-mediated regulation has been implicated in anticancer drug resistance (Stark et al., 2011) . It is thus conceivable that gain of binding of SF2/ASF and loss of binding of hnRNPs contributes to splicing regulation with consequences for tumor progression.
Synonymous Mutations in Oncogenes Are Associated with Abnormal Splicing
We examined >2,000 cancer exomes that had matching RNA sequencing (RNA-seq) measurements, searching for splicing irregularities associated with synonymous mutations by employing a multivariate outlier measure, the Mahalanobis distance (De Maesschalck et al., 2000; Mahalanobis, 1936) . This method accounts for the correlation structure between variables (exon levels), as well as for the variability of each variable, and can be understood as a multivariate generalization of a Z score. This revealed a strong association between synonymous mutations and differential exon usage profiles in the most recurrently mutated oncogenes (p = 0.0004; Figures 5A and 5C ). This is not the case for samples harboring nonsynonymous mutations in the same genes ( Figure 5C ) or for the splicing of non-cancer genes with synonymous mutations ( Figure 5C ). The oncogenes exhibit no significant change in their overall expression level in the samples with synonymous mutations ( Figure 5D ). Importantly, the strongest deviations in the splicing patterns (top 10% by outlier score; rightmost bar in Figure 5A ) are the ones most enriched in the synonymous-mutated oncogenes (p = 2 3 10 À6 ), with some enrichment also noted for moderate changes in splicing patterns (top 30%; Figure 5A ; p = 0.002). Across tumor types, the frequency of aberrant splicing profiles detectable in the RNA-seq data allowed us to conservatively estimate that approximately half of the putative synonymous drivers are associated with splicing changes ( Figure 5B) . Moreover, we note that splicing alterations may be more frequent for some oncogenes (e.g., ITK, ALK, IDH1, or BCL6) than for others ( Figure 5E ), although other oncogenes (including EGFR, KDR, and PDGFRA) also contain multiple instances of synonymous mutations in samples with significantly outlying exon usage profiles ( Figure 5E ).
Cancer-Associated Synonymous Mutations Alter Splicing in Minigene Assays
To further validate our findings, we experimentally evaluated the effects of 12 synonymous mutations in five oncogenes (Extended Experimental Procedures) by examining changes in splicing patterns induced by the mutations using minigenes transfected in HeLa cells. Briefly, for each mutation tested, exonic and flanking intronic sequences of wild-type and mutant were cloned to replace an alternative cassette exon in a reporter plasmid (Orengo et al., 2006) and the patterns of exon inclusion/skipping of transcripts derived from the minigene were analyzed (see Experimental Procedures). The examined oncogene exons were selected such that the wild-type minigene exhibited measurable levels of both exon inclusion and skipping in this experimental setup. In total, six of the mutations affected alternative splicing: two mutations in exon 15 of JAK3, one mutation in exon 14 of NTRK1, and two mutations in exon 4 and one in exon 13 of ITK. In all cases, the mutations are located in the tyrosine kinase domains of the corresponding proteins, except for ITK exon 4, which overlaps a pleckstrin homology domain. The two mutations in JAK3 exon 15 affect neighboring codons and were predicted to lead to ESS losses in two overlapping ESS hexamers ( Figure 6A ); they induced a clear reduction ($14%-23%) in exon-skipping frequency in the splicing assay ( Figure 6A) . Similarly, the NTRK1 mutation resulted in a reduction in exon skipping ( Figure 6B , $23%), consistent with its prediction as an ESE gain event; we also observed an increased abundance of an aberrantly spliced product (asterisk in Figure 6B ). Finally, in the ITK oncogene, the two mutations in exon 4 were predicted to result in ESS losses ( Figure 6D ). Both mutations decreased the skipping/inclusion ratio and, moreover, increased the overall levels of mRNA ( Figure 6D) . A third mutation in ITK was predicted to cause both ESE gain and ESE loss events in overlapping motifs in exon 13 and led to an increase in exon skipping ($10%; Figure 6C ).
In all cases except ITK exon 4, exon skipping is predicted to result in a frameshift, suggesting that increased inclusion might lead to increased expression of the full-length isoform and consequently higher oncogene activity. Taken together, the detection of splicing changes in 6 out of 12 (50%; 95% CI: 21%-79%) of the tested cases is consistent with the estimate derived from the RNA-seq data that approximately half of synonymous drivers in oncogenes have effects on alternative splicing.
Recurrent Synonymous Mutations in TP53 Inactivate Splice Sites
Although, considered together, tumor suppressors did not show an enrichment of synonymous mutations, when considered individually, one tumor suppressor, TP53, was strongly enriched ( Figure 6E ; 3.993). The TP53-synonymous mutations were also extremely recurrent and, in contrast to those in oncogenes, target nucleotides directly adjacent to splice sites (75% of the synonymous mutations recur in three such nucleotides). Indeed, upon masking the terminal 2 nt of its exons, TP53 shows no synonymous mutation enrichment ( Figure 6E ), consistent with previous estimates that most synonymous mutations in TP53 are neutral (Strauss, 2000) . However, an enrichment in evolutionarily conserved sites suggests a functional role for a subset of mutations (Lamolle et al., 2006) .
Recurrently targeted synonymous sites in TP53 include the 3 0 terminal nucleotide of TP53 exon 4 (in codon 125; Figure 6F ). Strikingly, a germline variant at the same site is a known cause of Li-Fraumeni syndrome, producing an aberrantly spliced TP53 mRNA that causes intron retention (Warneford et al., 1992) and activation of cryptic splice sites (Varley et al., 1998) . In addition, the 3 0 terminal nucleotide of exon 6 is also recurrently mutated (codon 224; Figure 6G ) with both synonymous and conservative missense changes (Glu > Asp). We confirmed using an in vivo splicing assay that this mutation results in aberrant splicing, activating a cryptic splice site 5 nt downstream from the end of exon 6 and resulting in a frameshifted mRNA (Figure 6H) . The wild-type splice site at the 5 0 of TP53 exon 6 has only a limited match to the consensus (AG/gtctgg versus AG/ gtaagt); the exonic G > A change further weakens it, being the likely cause for the use of the downstream cryptic splice site that has a G as the 3 0 nucleotide of the extended exon 6. Moreover, we found a third recurrently mutated site in TP53 with similar properties, where the 3 0 terminal G of exon 9 is commonly lost (codon 331; Figure S5 ). Thus, at least one tumor suppressor gene is also targeted by recurrent synonymous mutations at multiple locations, but, in contrast to those in oncogenes, these mutations inactivate splice sites.
Dosage-Sensitive Oncogenes Have an Excess of Mutations in Their 3
0 UTRs Finally, we reasoned that our analytical approach might also be useful for identifying additional classes of recurrent mutations in cancer genomes. We focused on mutations in untranslated regions because, similar to synonymous mutations, these have not been extensively investigated and are known to be important for regulating gene expression. In contrast to the situation with synonymous mutations, missense-activated oncogenes and the recurrently mutated oncogenes showed no enrichment for mutations in their 3 0 UTRs ( Figure 7A ). However, one set of oncogenes did show a clear enrichment of mutations in 3 0 UTRs: those oncogenes that can be activated by amplification (1.193, p = 0.03; Figure 7A ).
We hypothesized, therefore, that other dosage-sensitive oncogenes-those activated by elevated expression-might also show an enrichment of somatic mutations in their 3 0 UTRs. Consistent with this, we found that cancer genes that are consistently overexpressed in human tumors ( Figure 7B ) and the orthologs of dosage-sensitive oncogenes identified in mice using transposon and retroviral screens ( Figure 7B ) both also showed an elevated rate of mutation in their 3 0 UTRs (1.263 and 1.403, p = 0.002 and 0.004; Figure 7A ). None of the three groups of dosage-sensitive oncogenes exhibited an excess of synonymous or intronic mutations ( Figure 7A ), demonstrating that regional mutation rate variations do not underlie the enrichments. When considering the opposite definitions of the above-cancer genes consistently underexpressed in human See also Figure S5 and Table S7 .
tumors or the orthologs of tumor suppressors found in mouse screens-neither group showed any 3 0 UTR mutation enrichment ( Figure 7A ). Moreover, 17 of the dosage-sensitive oncogenes were R23 enriched with 3 0 UTR mutations, of which ten genes were individually significant at FDR % 10% ( Figure 7C ). Within the highly enriched dosage-sensitive oncogenes, the 3 0 UTR mutations clustered ( Figure 7D ), and we provide the mutation clusters in the significantly enriched genes as a resource ( Figure S5 ; Table S7 ). Thus, our method was able to identify another unexpected enrichment of mutations in cancer genomes, predicting that dosage-sensitive oncogenes may be recurrently activated by mutations in their 3 0 UTRs.
DISCUSSION
The large-scale sequencing of cancer genomes provides an opportunity to reassess the types of mutations that contribute to cancer in an unbiased manner. From their excess in oncogenes (see Extended Experimental Procedures), we estimate that approximately one in five synonymous mutations in all known oncogenes reported to-date in cancer genome projects have been selected, with this proportion rising to approximately one in two for the oncogenes most relevant to each cancer type.
From the frequency at which synonymous changes occur compared to nonsynonymous mutations within oncogenes (see Extended Experimental Procedures), synonymous mutations represent $6%-8% of all driver mutations due to singlenucleotide changes in these genes. Therefore, as part of their standard analyses, future cancer genome studies should test for enrichment and recurrence of synonymous changes. Moreover, our combined computational and experimental analyses estimated that approximately half of synonymous drivers alter splicing. In future experimental work, it will be important to further dissect how these changes in splicing influence cancer progression and how they can be therapeutically targeted (Bonnal et al., 2012) . In addition to their effects on splicing, it is known that synonymous mutations can alter protein folding (KimchiSarfaty et al., 2007; Zhang et al., 2009; Zhou et al., 2013) , and our preliminary analyses suggest that this might also be relevant in cancer ( Figure S4) .
As illustrated by our discovery of selected mutations in the 3 0 UTRs of dosage-sensitive oncogenes, the general approach presented here may be useful for identifying additional classes of unexpected cancer driver mutations and thus provide a fuller understanding of how changes in cancer genomes contribute to tumor progression in individual patients.
EXPERIMENTAL PROCEDURES
For a more exhaustive description of the computational analyses, as well as the minigene splicing experiments, please refer to Extended Experimental Procedures.
Genomic Data, Cancer Genes, and Matched Sets Somatic mutations in 3,851 cancer exomes were from the Cancer Genome Atlas (TCGA) Data Portal (Zhang et al., 2011) and from the exome sequencing studies in COSMIC v61 (Forbes et al., 2011 ) that reported synonymous mutations (Table S2 ). Somatic mutations in 167 cancer genomes from the International Cancer Genome Consortium Data Portal v8 and additional publications (Table S2 ) were used to determine 1 Mb/200 kb regional mutation rates. Of 219 additional whole genomes from the TCGA project (Table S2) , mutations in 50 leukemias were from Cancer Genome Atlas Research Network (2013), whereas for others, including the 24 glioblastomas (Brennan et al., 2013) , aligned short reads were downloaded from cgHub and somatic mutations called using Strelka 1.0.6 (Saunders et al., 2012) . cDNAs from COSMIC v61 were matched to transcript models from RefSeq or Ensembl in the University of California, Santa Cruz (UCSC) ''golden path'' repository. Nonunique genomic regions in the ''CRG Alignability 36'' UCSC track were masked out and sequencing error-prone motifs checked for ( Figure S6 ). The regional mutation rates for different cancers ( Figure 1B) , gene mRNA levels in ten tissues ( Figure S7 ), and GC3 content in cDNA, together with H3K9me3 (CD4 + cells)
and Repli-Seq (NHEK cells, wgEncodeEH002249) signal averaged over 1 Mb windows, was used to find matched sets using a genetic algorithm (GA)-based optimization. The GA minimizes the cDNA length-weighted Kolmogorov-Smirnov distance of the distributions of mutation rates and other genomic features to the cancer gene set in question by iteratively ''recombining'' and ''mutating'' the matched-set candidates. Matched sets for single cancer genes were constructed from 200 genes closest by Euclidian distance using trimmed and normalized mutation rates, mRNA levels, etc. Mutation enrichment is calculated as a relative risk of mutation compared to the matched set and significance determined by a Z-test on the standard error of the log RR. The tissue-specific oncogenes/tumor suppressors are those individually significantly enriched with either missense or nonsense mutations in a specific tissue (median FDR across tissues = 7.3%; list in Table S4 ).
Analyses of Splicing Motifs and Data
Complete sets of 176 ESSs from Wang et al. (2004) and 238 ESEs from Fairbrother et al. (2002), as well as the top 200 ESEs and ESSs from Ke et al. (2011) , were tested for enrichments (using c 2 tests) of gain versus loss events caused by synonymous mutations in oncogenes, compared to the matched sets, missense mutations, or randomized positions. Splice-site strength was determined as the average log likelihood of the nucleotides in the splice site, given the consensus position weight matrixes (PWMs) in SpliceRack (Sheth et al., 2006) . Motifs around the ESE/ESS-altering synonymous mutations were discovered in the mutated site and its ±5 nt context by the MEME 4.9.0 server (Bailey et al., 2009 ) with motif size = 6-8 and other parameters at default. Sequences in the large ESE gain cluster were submitted to ESEFinder 3.0 (Smith et al., 2006) , which classifies whether each sequence will bind a splicing factor based on an empirical threshold. We searched the PWM of a major ESS loss cluster against CISBP-RNA 0.6 (Ray et al., 2013) to find human RNA-binding proteins with significantly similar binding sites. The shown SF2/ASF motif is from Smith et al. (2006) and the hnRNP H2 motif is from Ray et al. (2013) . Available data from the TCGA ''RNASeqV2'' pipeline (October 2013) were matched to existing TCGA samples with exonic mutations. 
